share_log

Altamira Therapeutics | 424B4: Prospectus

Altamira Therapeutics | 424B4: Prospectus

Altamira Therapeutics | 424B4：募资说明书
美股sec公告 ·  04/17 16:25
Moomoo AI 已提取核心信息
Altamira Therapeutics Ltd., a Bermuda-based biopharmaceutical company, has announced a prospectus relating to the resale of up to 2,000,000 common shares by selling shareholder Lincoln Park Capital Fund, LLC (LPC). The shares have a par value of USD 0.002 each and are traded on The Nasdaq Capital Market under the symbol 'CYTO'. The resale is part of a Purchase Agreement dated December 5, 2022, which allows Altamira to issue and sell shares to LPC at its discretion, subject to certain conditions. Altamira will not sell any securities under this prospectus and will not receive proceeds from LPC's resale of shares. However, the company may receive up to $8,814,200 from the sale of Purchase Shares to LPC over time. LPC, considered an 'underwriter', may sell the shares at varying prices. The closing price of Altamira's common shares on Nasdaq as of April 5, 2024, was $1.975 per share. The company, identified as a 'foreign private issuer', is subject to reduced reporting requirements and has highlighted the investment risks in its common shares. The prospectus date is April 17, 2024.
Altamira Therapeutics Ltd., a Bermuda-based biopharmaceutical company, has announced a prospectus relating to the resale of up to 2,000,000 common shares by selling shareholder Lincoln Park Capital Fund, LLC (LPC). The shares have a par value of USD 0.002 each and are traded on The Nasdaq Capital Market under the symbol 'CYTO'. The resale is part of a Purchase Agreement dated December 5, 2022, which allows Altamira to issue and sell shares to LPC at its discretion, subject to certain conditions. Altamira will not sell any securities under this prospectus and will not receive proceeds from LPC's resale of shares. However, the company may receive up to $8,814,200 from the sale of Purchase Shares to LPC over time. LPC, considered an 'underwriter', may sell the shares at varying prices. The closing price of Altamira's common shares on Nasdaq as of April 5, 2024, was $1.975 per share. The company, identified as a 'foreign private issuer', is subject to reduced reporting requirements and has highlighted the investment risks in its common shares. The prospectus date is April 17, 2024.
总部位于百慕大的生物制药公司Altamira Therapeutics Ltd. 宣布了一份招股说明书，内容涉及出售股东林肯公园资本基金有限责任公司（LPC）转售多达200万股普通股。这些股票的面值为每股0.002美元，在纳斯达克资本市场上交易，股票代码为 “CYTO”。此次转售是2022年12月5日收购协议的一部分，该协议允许阿尔塔米拉在某些条件下自行向LPC发行和出售股票。阿尔塔米拉不会根据本招股说明书出售任何证券，也不会从LPC转售股票中获得收益。但是，随着时间的推移，该公司可能通过向LPC出售购买股份获得高达8,814,200美元的收入。被视为 “承销商” 的LPC可能会以不同的价格出售股票。截至2024年4月5日，阿尔塔米拉在纳斯达克的普通股的收盘价为每股1.975美元。该公司被认定为 “外国私人发行人”，其报告要求有所降低，并强调了其普通股的投资风险。招股说明书日期为2024年4月17日。
总部位于百慕大的生物制药公司Altamira Therapeutics Ltd. 宣布了一份招股说明书，内容涉及出售股东林肯公园资本基金有限责任公司（LPC）转售多达200万股普通股。这些股票的面值为每股0.002美元，在纳斯达克资本市场上交易，股票代码为 “CYTO”。此次转售是2022年12月5日收购协议的一部分，该协议允许阿尔塔米拉在某些条件下自行向LPC发行和出售股票。阿尔塔米拉不会根据本招股说明书出售任何证券，也不会从LPC转售股票中获得收益。但是，随着时间的推移，该公司可能通过向LPC出售购买股份获得高达8,814,200美元的收入。被视为 “承销商” 的LPC可能会以不同的价格出售股票。截至2024年4月5日，阿尔塔米拉在纳斯达克的普通股的收盘价为每股1.975美元。该公司被认定为 “外国私人发行人”，其报告要求有所降低，并强调了其普通股的投资风险。招股说明书日期为2024年4月17日。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息